All updated as on -
In 2022, the anti-venom market was estimated to be worth $0.9 billion. During the forecast period (2023-2030), the Anti-Venom market industry is expected to develop from 2023's projected value of USD 0.68 Billion to 2030's predicted value of USD 1.30 Billion, a CAGR (compound annual growth rate) of 9.90%. Market expansion is being fueled by a number of factors, including an increase in snake bite sufferers and spending on healthcare R&D.
Anti-venom, also known as venom antiserum, is a drug used to alleviate the symptoms of a venomous bite or sting from a variety of species. This includes but is not limited to snakes, spiders, scorpions, and even marine organisms like jellyfish and cone snails. Anti-venom is obtained by injecting small amounts of the venom into animals like horses, sheep, or goats, eliciting an immunological response that yields antibodies that can then be extracted and purified. Life-threatening problems, like respiratory failure or organ damage, can be avoided with the use of anti-venom, which works by neutralising the toxins and counteracting the effects of the venom. Depending on the patient's history and physical, as well as geographical, clinical, and pathologic characteristics, it is widely used in the treatment of poisonous bites and stings around the world.
Snake, scorpion, spider, jellyfish, stone fish, and other dangerous animal bites can be treated using anti-venom. You can classify anti-venoms as either monovalent or polyvalent. The World Health Organisation (WHO) defines monovalent anti-venoms as those that are only effective against one species of venomous snake or a small group of closely related species whose venoms cross-neutralize effectively with anti-venom. In order to produce polyvalent anti-venoms, the plasma of animals immunised with a combination of venoms from several venomous snake species is fractionated.
People, especially those living in rural regions, are regularly exposed to the public health danger of snakebite envenoming. One of the primary motivating elements for the development of safe, effective, and reasonably priced anti-venoms is the prevalence of occupational injuries it causes among various agricultural workers and hunters. Additionally, individuals in tropical areas are at risk for bites by nocturnal and highly venomous snakes due to the prevalence of open-plan dwellings and the practise of sleeping on the floor. Kidney failure, paralysis so severe that breathing is impeded, bleeding disorders that can result in deadly haemorrhage, and severe local tissue degradation that can cause permanent handicap and result in limb amputation are all examples of such medical issues. As a result, there has been a surge in interest in anti-venoms all across the world. Additionally, snake venom detection kits using a fast enzyme immunoassay for in vitro detection and immunological identification of snake venom in bite site samples, urine, plasma, blood, or other tissues and body fluids have been introduced. This is expected to propel the market as a whole and provide lucrative growth prospects for industry participants.
The rising incidence of animal bites including snake and scorpion bites is a key factor propelling the compound annual growth rate (CAGR) of the anti-venom market. Poisonous bites and stings are on the rise globally, especially in tropical regions and among farmworkers and hunters. The broad availability of products at affordable rates, as well as the growing importance of avoiding snake bites, all contribute to the market's optimistic outlook. Government efforts, including as education and training programmes and major investments in research and development of novel anti-venom medicines, are also contributing to the growth of the industry.
More people are also venturing to far-flung locales, increasing the risk of encountering snakes and other venomous animals. Islands, dry plains, tropical forests, and wild safaris are all examples of this. Several technological advancements in manufacturing, as well as advances in biotechnology and healthcare, are fueling the development of more effective anti-venom drugs, which in turn is boosting the market. The growth of the pharmaceutical market will be supported by rising levels of consumer spending and government funding for pharmaceutical R&D. Rapid enzyme immunoassay-based snake venom detection kits have allowed for the in vitro detection and immunological identification of snake venom in bite site samples, plasma, blood, and other tissues and body fluids. As a result, the rising frequency of these assaults is contributing to the development of the global market.
Report Coverage
Global Anti-Venom research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Anti-Venom report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Anti-Venom competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Anti-Venom market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Anti-Venom market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Anti-Venom market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc. and Rare Disease Therapeutics Inc., Stryker Corporation, Smiths Medical, Allison Medical Inc., Owen Mumford Ltd., Ypsomed Holding AG, Terumo Corporation, Hamilton Company, Medline Industries Inc., UltiMed Inc., and others
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Anti-Venom market based on the below-mentioned segments:
Global Anti-Venom Market, By Type
Polyvalent
Monovalent
Others
Global Anti-Venom market, By Species
Snake
Spider
Scorpion
Others
Global Anti-Venom Market, By End User
Clinics
Hospitals
Ambulatory surgical centers
Others
Global Anti-Venom market, Regional Analysis
Anti-venom, also known as venom antiserum, is a drug used to alleviate the symptoms of a venomous bite or sting from a variety of species. This includes but is not limited to snakes, spiders, scorpions, and even marine organisms like jellyfish and cone snails. Anti-venom is obtained by injecting small amounts of the venom into animals like horses, sheep, or goats, eliciting an immunological response that yields antibodies that can then be extracted and purified. Life-threatening problems, like respiratory failure or organ damage, can be avoided with the use of anti-venom, which works by neutralising the toxins and counteracting the effects of the venom. Depending on the patient's history and physical, as well as geographical, clinical, and pathologic characteristics, it is widely used in the treatment of poisonous bites and stings around the world.
Snake, scorpion, spider, jellyfish, stone fish, and other dangerous animal bites can be treated using anti-venom. You can classify anti-venoms as either monovalent or polyvalent. The World Health Organisation (WHO) defines monovalent anti-venoms as those that are only effective against one species of venomous snake or a small group of closely related species whose venoms cross-neutralize effectively with anti-venom. In order to produce polyvalent anti-venoms, the plasma of animals immunised with a combination of venoms from several venomous snake species is fractionated.
People, especially those living in rural regions, are regularly exposed to the public health danger of snakebite envenoming. One of the primary motivating elements for the development of safe, effective, and reasonably priced anti-venoms is the prevalence of occupational injuries it causes among various agricultural workers and hunters. Additionally, individuals in tropical areas are at risk for bites by nocturnal and highly venomous snakes due to the prevalence of open-plan dwellings and the practise of sleeping on the floor. Kidney failure, paralysis so severe that breathing is impeded, bleeding disorders that can result in deadly haemorrhage, and severe local tissue degradation that can cause permanent handicap and result in limb amputation are all examples of such medical issues. As a result, there has been a surge in interest in anti-venoms all across the world. Additionally, snake venom detection kits using a fast enzyme immunoassay for in vitro detection and immunological identification of snake venom in bite site samples, urine, plasma, blood, or other tissues and body fluids have been introduced. This is expected to propel the market as a whole and provide lucrative growth prospects for industry participants.
The rising incidence of animal bites including snake and scorpion bites is a key factor propelling the compound annual growth rate (CAGR) of the anti-venom market. Poisonous bites and stings are on the rise globally, especially in tropical regions and among farmworkers and hunters. The broad availability of products at affordable rates, as well as the growing importance of avoiding snake bites, all contribute to the market's optimistic outlook. Government efforts, including as education and training programmes and major investments in research and development of novel anti-venom medicines, are also contributing to the growth of the industry.
More people are also venturing to far-flung locales, increasing the risk of encountering snakes and other venomous animals. Islands, dry plains, tropical forests, and wild safaris are all examples of this. Several technological advancements in manufacturing, as well as advances in biotechnology and healthcare, are fueling the development of more effective anti-venom drugs, which in turn is boosting the market. The growth of the pharmaceutical market will be supported by rising levels of consumer spending and government funding for pharmaceutical R&D. Rapid enzyme immunoassay-based snake venom detection kits have allowed for the in vitro detection and immunological identification of snake venom in bite site samples, plasma, blood, and other tissues and body fluids. As a result, the rising frequency of these assaults is contributing to the development of the global market.
Report Coverage
Global Anti-Venom research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Anti-Venom report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Anti-Venom competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Anti-Venom market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc. and Rare Disease Therapeutics Inc., Stryker Corporation, Smiths Medical, Allison Medical Inc., Owen Mumford Ltd., Ypsomed Holding AG, Terumo Corporation, Hamilton Company, Medline Industries Inc., UltiMed Inc., and others |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Anti-Venom Market from 2021 to 2030.
- Market Forecast for Anti-Venom Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Anti-Venom competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Anti-Venom
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Anti-Venom market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Anti-Venom market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc. and Rare Disease Therapeutics Inc., Stryker Corporation, Smiths Medical, Allison Medical Inc., Owen Mumford Ltd., Ypsomed Holding AG, Terumo Corporation, Hamilton Company, Medline Industries Inc., UltiMed Inc., and others
Primary Target Market
- Market Players of Anti-Venom
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Anti-Venom market based on the below-mentioned segments:
Global Anti-Venom Market, By Type
Polyvalent
Monovalent
Others
Global Anti-Venom market, By Species
Snake
Spider
Scorpion
Others
Global Anti-Venom Market, By End User
Clinics
Hospitals
Ambulatory surgical centers
Others
Global Anti-Venom market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive anti venom market market research and competitor analysis for your business to help you develop more profound insights into the anti venom market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the anti venom market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.